Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Fiera Capital Corp reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,354,469 shares of the company's stock after selling 46,721 shares during the quarter. Fiera Capital Corp owned approximately 1.11% of Apellis Pharmaceuticals worth $39,063,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its stake in Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company's stock valued at $61,845,000 after purchasing an additional 1,409,707 shares during the period. Iron Triangle Partners LP bought a new position in Apellis Pharmaceuticals in the 1st quarter worth about $32,329,000. Bank of New York Mellon Corp boosted its stake in Apellis Pharmaceuticals by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company's stock worth $13,242,000 after purchasing an additional 22,273 shares during the period. Altitude Crest Partners Inc. boosted its stake in Apellis Pharmaceuticals by 88.7% in the 1st quarter. Altitude Crest Partners Inc. now owns 287,277 shares of the company's stock worth $16,886,000 after purchasing an additional 135,077 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company's stock worth $9,177,000 after purchasing an additional 190,420 shares during the period. Institutional investors own 96.29% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. William Blair assumed coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an "outperform" rating on the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. JPMorgan Chase & Co. lowered their price target on Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating on the stock in a report on Friday, September 13th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Finally, Mizuho lowered their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a "neutral" rating on the stock in a report on Thursday, October 24th. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $51.06.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Price Performance

APLS traded up $1.24 on Friday, hitting $29.98. 4,756,447 shares of the company were exchanged, compared to its average volume of 3,080,364. The firm has a fifty day simple moving average of $31.02 and a two-hundred day simple moving average of $37.02. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 4.18. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the business earned ($1.17) earnings per share. Apellis Pharmaceuticals's revenue was up 78.3% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.5 earnings per share for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).